ABL2 and urinary bladder carcinoma: Conversely, miR-27a, miR-205, miR-143, and miR-369 targeted oncogenes such as Death-Associated Protein Kinase 1 (DAPK1), Caspase 3 (CASP3), DNA Methyltransferase 1 (DNMT1), Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2), BCL2 Apoptosis Regulator (BCL2), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA), Protein Kinase Inhibitor Alpha (PKIA), and ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase (ABL2), which are known to be dysregulated in bladder cancer and associated with aggressive tumor behavior [41,45,46,47,48,49,50] (Supplementary Table S2E–H).